Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-dose expansion Phase 2/3 clinical study to evaluate the efficacy and safety of YOLT-202 in adult patients with Alpha-1 Antitrypsin Deficiency (AATD).

Next Previous
Trial Profile

A single-dose expansion Phase 2/3 clinical study to evaluate the efficacy and safety of YOLT-202 in adult patients with Alpha-1 Antitrypsin Deficiency (AATD).

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 25 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YOLT 202 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Therapeutic Use
  • Sponsors YolTech Therapeutics

Most Recent Events

  • 25 Mar 2026 New trial record
  • 14 Mar 2026 According to YolTech Therapeutics media release, the the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for YOLT-202,to initiate this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top